DEMOGRAPHIC AND CLINICAL CHARACTERISTICS OF MULTIPLE MYELOMA PATIENTS IN LATIN AMERICA VTM Hungria; D Trufelli; K Nakajima; R Gaiolla; K Galvez; G Remaggi; R Bitterncourt; A Maiolino; N Schutz; G Quintero;

DARATUMUMAB + BORTEZOMIB, LENALIDOMIDE, AND DEXAMETHASONE (DVRD) VS VRD IN TRANSPLANT-INELIGIBLE (TIE)/TRANSPLANT-DEFERRED (TD) NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): PHASE 3 CEPHEUS TRIAL CYTOGENETIC SUBGROUP ANALYSIS NJ Bahlis; SZ Usmani; T Facon; S Zweegman; C Venner; M Braunstein; L Pour; J Marti; A Maiolino; V Hungria;

DARATUMUMAB PLUS BORTEZOMIB, LENALIDOMIDE, AND DEXAMETHASONE (DVRD) IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): SUBGROUP ANALYSIS OF TRANSPLANT- INELIGIBLE (TIE) PATIENTS IN THE PHASE 3 CEPHEUS STUDY T Facon; S Zweegman; V Hungria; NJ Bahlis; CP Venner; M Braunstein; L Pour; J Marti; A Maiolino; SZ Usmani;